Phase 1 results confirm investigational drug-candidate G1090N has a favorable safety and tolerability profile, supporting further clinical evaluationCompelling anti-inflammatory activity of G1090N was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback